Abbisko Cayman Limited
HKSE: 2256.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yao-Chang Xu
- Employees
- 281
- Headquarters
- Shanghai, China
- IPO year
- 2021
- Market cap
- HK$7.8B
- Website
- https://www.abbisko.com
Loading 2256…
Loading profile data…Frequently asked questions about 2256
What does Abbisko Cayman Limited (2256.HK) do?
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company's primary product ca...
Where does 2256.HK trade?
Abbisko Cayman Limited (2256.HK) trades on the Hong Kong Stock Exchange.
What sector is 2256.HK in?
Abbisko Cayman Limited (2256.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Abbisko Cayman Limited?
Yao-Chang Xu is the chief executive officer of Abbisko Cayman Limited (2256.HK).
Where is Abbisko Cayman Limited headquartered?
Abbisko Cayman Limited is headquartered in China.
Does 2256.HK pay a dividend?
Abbisko Cayman Limited (2256.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2256.HK go public?
Abbisko Cayman Limited (2256.HK) completed its initial public offering in 2021.